Aripiprazole augmentation in poor insight obsessive-compulsive disorder: A case report

Annals of General Psychiatry

Volumn 7, Issue , 2008, Pages

  Fornaro, Michele ^a   Gabrielli, Filippo ^a   Mattei, Chiara ^a   Vinciguerra, Valentina ^a   Fornaro, Pantaleo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; ATTITUDE TO ILLNESS; CASE REPORT; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MORNING DOSAGE; NEUROPSYCHOLOGICAL TEST; OBSESSIVE COMPULSIVE DISORDER; PATIENT ATTITUDE; POOR INSIGHT OBSESSIVE COMPULSIVE DISORDER;

EID: 58249136304     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-7-26     Document Type: Article

References (13)

1. Bloch MH Landeros-Weisenberger A Kelmendi B Coric V Bracken MB Leckman JF A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder Mol Psychiatry 2006, 11:622-632. 10.1038/sj.mp.4001823 16585942
2. Alonso P Menchon JM Segalas C Jaurrieta N Jimenez-Murcia S Cardoner N Labad J Real E Pertusa A Vallejo J Clinical implications of insight assessment in obsessive-compulsive disorder Compr Psychiatry 2008, 49:305-312. 10.1016/j.comppsych.2007.09.005 18396191
3. Ravi Kishore V Samar R Janardhan Reddy YC Chandrasekhar CR Thennarasu K Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder Eur Psychiatry 2004, 19:202-208. 10.1016/ j.eurpsy.2003.12.005 15196601
4. Steketee G Disability and family burden in obsessive-compulsive disorder Can J Psychiatry 1997, 42:919-928. 9429061
5. Goodman WK Price LH Rasmussen SA Mazure C Fleischmann RL Hill CL Heninger GR Charney DS The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability Arch Gen Psychiatry 1989, 46:1006-1011. 2684084
6. Eisen JL Phillips KA Baer L Beer DA Atala KD Rasmussen SA The Brown Assessment of Beliefs Scale: Reliability and validity Am J Psychiatry 1998, 155:102-108. 9433346
7. Cook PE Goldberg JO Van Lieshout RJ Benefits of switching from typical to atypical antipsychotic medications: A longitudinal study in a community-based setting Can J Psychiatry 2002, 47:870-874. 12500758
8. American Psychiatric Association American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders Arlington, VA, USA: APA 2006.
9. Fleischhacker WW Aripiprazole Expert Opin Pharmacother 2005, 6:2091-2101. 10.1517/14656566.6.12.2091 16197361
10. Connor KM Payne VM Gadde KM Zhang W Davidson JR The use of aripiprazole in obsessive-compulsive disorder: Preliminary observations in 8 patients J Clin Psychiatry 2005, 66:49-51. 15669888
11. Wood M Reavill C Aripiprazole acts as a selective dopamine D2 receptor partial agonist Expert Opin Investig Drugs 2007, 16:771-775. 10.1517/ 13543784.16.6.771 17501690
12. Bortolozzi A Diaz-Mataix L Toth M Celada P Artigas F In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain Psychopharmacology (Berlin) 2007, 191:745-758. 10.1007/s00213-007-0698-y
13. Sarkar R Klein J Kruger S Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder Psychopharmacology (Berlin) 2008, 197:687-688. 10.1007/s00213-008-1091-1